據報小米(01810.HK)轉讓多個「kimi」商標予北京月之暗面
內媒報道,天眼查資料顯示,小米(01810.HK)近日將多個「kimi」商標轉讓予北京月之暗面科技,上述商標首次申請於2013年,目前上述商標狀態多為已註冊。
北京月之暗面科技於2023年4月成立,經營範圍包括軟件開發、軟件銷售、人工智能基礎軟件開發、人工智能應用軟件開發、電腦系統服務、資訊科技諮詢服務等,由楊植麟、周宇鑫、吳育昕等5位股東共同持股。
公開資訊顯示,Kimi是北京月之暗面科技於2023年10月9日推出的首款智能助手,主要應用場景為專業學術論文的翻譯與理解、輔助分析法律問題、快速理解API開發文件等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.